Cancer Research UK logo.
SearchDonate
  • Search

A study looking at tolinapant with pembrolizumab to treat solid cancers (ASTEROID)

Overview

Cancer types:

All cancer types

Status:

Open

Phase:

Phase 1

Details

This study is looking at tolinapant (ASTX660) with pembrolizumab for people with cancer that has spread and whose treatment has stopped working.

It is for people with a . This is any cancer apart from a blood cancer such as leukaemia.

You pronounce tolinapant as tuh-lin-a-pant.

Cancer Research UK supports this study.

Recruitment start: 15 March 2022

Recruitment end: 30 April 2026

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Juanita Lopez

Supported by

Cancer Research UK

Institute of Cancer Research (ICR)

Other information

This is Cancer Research UK trial number CRUK/21/016.

Last reviewed: 02 Apr 2026

CRUK internal database number: 19938

Help and support